Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
PubWeight™: 0.77‹?›
Published in Breast on June 20, 2016
Authors
G Curigliano1, P Gómez Pardo2, F Meric-Bernstam3, P Conte4, M P Lolkema5, J T Beck6, A Bardia7, M Martínez García8, F Penault-Llorca9, S Dhuria10, Z Tang10, N Solovieff11, M Miller10, E Di Tomaso11, S A Hurvitz12
Author Affiliations
1: Istituto Europeo di Oncologia, via Ripamonti 435, 20141, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
2: Servicio Oncologia Médica, Vall d'Hebron University Hospital, Vall d'Hebron 119-129, 08035, Barcelona, Spain.
3: The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
4: Istituto Oncologico Veneto, Via Gattamelata 64, 35128, Padua, Italy; University of Padova, Via Giustiniani 22, 35121, Padua, Italy.
5: University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands; Erasmus Medical Center Cancer Institute, Erasmus Medical Center, s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
6: Highlands Oncology Group, 3232 N North Hills Blvd, Fayetteville, AR, 72703, USA.
7: Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
8: Oncología Médica, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.
9: Centre Jean Perrin, Unicancer and EA 4677 Université d'Auvergne, 58 rue Montalembert, 63011, Clermont-Ferrand, France.
10: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA.
11: Novartis Institutes for BioMedical Research, 230 Massachusetts Avenue, Cambridge, MA, 02139, USA.
12: University of California, Los Angeles, 2825 Santa Monica Blvd, Suite 211, Santa Monica, CA, 90404, USA.